  The severe acute respiratory syndrome coronavirus 2 outbreak in Chinas Hubei
area in late 2019 has now created a global pandemic that has spread to over 150
countries. In most people, COVID 19 is a respiratory infection that produces
fever, cough, and shortness of breath. Patients with severe COVID 19 may
develop ARDS. MSCs can come from a number of places, such as bone marrow,
umbilical cord, and adipose tissue. Because of their easy accessibility and low
immunogenicity, MSCs were often used in animal and clinical research. In recent
studies, MSCs have been shown to decrease inflammation, enhance lung
permeability, improve microbial and alveolar fluid clearance, and accelerate
lung epithelial and endothelial repair. Furthermore, MSC-based therapy has
shown promising outcomes in preclinical studies and phase 1 clinical trials in
sepsis and ARDS. In this paper, we posit the therapeutic strategies using MSC
and dissect how and why MSC therapy is a potential treatment option for COVID
19 induced ARDS. We cite numerous promising clinical trials, elucidate the
potential advantages of MSC therapy for COVID 19 ARDS patients, examine the
detriments of this therapeutic strategy and suggest possibilities of subsequent
research.
